Market Overview

Hyperinsulinemia| A Drug Pipeline Analysis Report 2018| Technavio

Share:

Technavio has announced their latest pipeline analysis report on the hyperinsulinemia
market
. The report includes a detailed analysis of the pipeline
molecules under investigation within the defined data collection period
to treat hyperinsulinemia.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180726005592/en/

Technavio has published a new report on the drug development pipeline for hyperinsulinemia, includin ...

Technavio has published a new report on the drug development pipeline for hyperinsulinemia, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report by Technavio
presents a detailed analysis of the market, including regulatory
framework, drug development strategies, recruitment strategies, and key
companies that are expected to play an essential role in the growth of
the market in the future.

This report is available at a USD 1,000 discount for a limited time
only:
View
market snapshot before purchasing

Hyperinsulinemia: Market overview

Hyperinsulinemia is a condition in which abnormally high levels of
insulin circulate in the body. Insulin is a hormone produced by the
pancreas to maintain the blood sugar levels in the body.
Hyperinsulinemia is associated with metabolic syndromes such as
hypertension, obesity, dyslipidemia, and glucose intolerance.
Hyperinsulinemia is caused due to insulin resistance, which means, the
body does not respond correctly to insulin. Hyperinsulinemia can lead to
high blood sugar levels as diabetes progresses, high blood pressure,
high cholesterol, and reduced blood fat levels.

According to a senior market research analyst at Technavio, "In
adults, hyperinsulinemia is often associated with type 2 diabetes.
However, in neonates, congenital hyperinsulinemia can be observed from
birth. Congenital hyperinsulinemia is caused by mutations in genes that
regulate the release of insulin, which is produced by beta cells in the
pancreas. The congenital hyperinsulinemia causes lethargy and
irritability in infants and young children. The severity of congenital
hyperinsulinemia varies widely among affected individuals, even among
members of the same family."

Hyperinsulinemia: Segmentation analysis

This pipeline analysis report segments the hyperinsulinemia market based
on RoA (oral, parenteral, intravenous, subcutaneous, and
subcutaneous/intravenous), therapeutic modality (small molecule,
monoclonal antibody, biological, and peptide), geographical segmentation
(the US and the UK) and recruitment status (completed, and recruiting).
It provides an in-depth analysis of the prominent factors influencing
the market, including drivers, opportunities, trends, and
industry-specific challenges.

Based on therapeutic modality, around 29% of the molecules that are
being investigated for the treatment of hyperinsulinemia are small
molecule.

Looking for more information on this market? Request
a free sample report

Technavio's sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio's comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at media@technavio.com.

View Comments and Join the Discussion!